J&J Seeks Permission For Phase-3 Trial of its Covid Vaccine
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Multinational pharma giant Johnson & Johnson has applied to India's drug regulator seeking permission to conduct phase-3 clinical trial of its single-dose Covid-19 vaccine in India as well as import license, sources said.

This comes close to the heels of the central government last week deciding to fast-track emergency approvals for all foreign-produced coronavirus jabs that have been given a similar nod by the World Health Organization or regulators in the United States, Europe, Britain, or Japan.

Such vaccines will be given emergency use approval mandating the requirement of post-approval parallel bridging clinical trial in place of conduct of local clinical trial under the provisions of the New Drugs and Clinical Trials Rules 2019, the health ministry had said.

According to sources, Johnson & Johnson had applied on April 12 in the Global Clinical Trial Division through the Sugam online portal, instead of applying to the biological division which deals with vaccines and other biologicals. "Due to the technicalities involved, Johnson & Johnson has resubmitted its application on April 19," a source said.

The J&J vaccine can be stored for up to three months in a temperature between 2 and 8 degrees Celsius. Johnson & Johnson's vaccine is a single-dose jab, whereas the three vaccines cleared by India so far are of doubles doses.

Source:
https://health.economictimes.indiatimes.com/news/pharma/jj-seeks-permission-for-phase-3-trial-of-its-single-shot-covid-vaccine-in-india-import-licence/82151915
Like
Comment
Share